DETERMINING THE THRESHOLD FOR ACCEPTABILITY OF AN ICER WHEN NATURAL HEALTH UNITS ARE USED
Main Article Content
Keywords
ICER, threshold, value
Abstract
.
References
1. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a Quality-Adjusted Life Year: in search of a standard. Med Decis Making 2000;20:332-42.
2. Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is costeffectiveness analysis equivalent to cost-benefit analysis? J Health Econ 1999;18:681-708.
3. McGregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoeconomics 2006;24(10):947-52.
4. Raisch DW. Understanding Quality-Adjusted Life Years and their application to pharmacoeconomic research. Ann Pharmacother 2000;34:906-14.
5. Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy 2005;74:77-84.
6. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
7. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37.
8. Drummond M, Torrance G, Mason J. Costeffectiveness league tables: more harm than good? Soc Sci Med 1993;37(1):33-40.
9. Yao G, Freemantle N, Flather M, Tharmanathan P, Coats A, Poole-Wilson PA. Long-term costeffectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure. Pharmacoeconomics 2008;26(10):879- 89.
10. Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008;26(4):329-39.
11. Orme ME, Jurewicz WA, Kumar N, McKechnie TL. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Pharmacoeconomics 2008;21(17):1263-76.
2. Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is costeffectiveness analysis equivalent to cost-benefit analysis? J Health Econ 1999;18:681-708.
3. McGregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoeconomics 2006;24(10):947-52.
4. Raisch DW. Understanding Quality-Adjusted Life Years and their application to pharmacoeconomic research. Ann Pharmacother 2000;34:906-14.
5. Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy 2005;74:77-84.
6. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
7. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37.
8. Drummond M, Torrance G, Mason J. Costeffectiveness league tables: more harm than good? Soc Sci Med 1993;37(1):33-40.
9. Yao G, Freemantle N, Flather M, Tharmanathan P, Coats A, Poole-Wilson PA. Long-term costeffectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure. Pharmacoeconomics 2008;26(10):879- 89.
10. Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008;26(4):329-39.
11. Orme ME, Jurewicz WA, Kumar N, McKechnie TL. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Pharmacoeconomics 2008;21(17):1263-76.